Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 24(11): 1252-1265, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37844597
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Brain Ischemia
/
Stroke
/
Kidney Neoplasms
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article